Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Background and Aims: The National Multiple Sclerosis Society and other expert organizations recommended that all patients with multiple sclerosis (MS) should be vaccinated against COVID-19. However, the effect of disease-modifying therapies (DMTs) on the efficacy to mount an appropriate immune respo...
Збережено в:
| Автори: | , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2021-04-01
|
| Серія: | Therapeutic Advances in Neurological Disorders |
| Онлайн доступ: | https://doi.org/10.1177/17562864211012835 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|